Advertisement

Search Results

Advertisement



Your search for ,had matches 18486 pages

Showing 12651 - 12700


hematologic malignancies
leukemia
lymphoma
multiple myeloma

Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma

In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...

lymphoma

For High-Grade and Aggressive Non-Hodgkin Lymphomas, Treat Adults Like Children

Outcomes for adults with high-grade and aggressive non-Hodgkin lymphomas (NHLs) appear to be better when these patients are treated with pediatric-inspired protocols, according to Mitchell S. Cairo, MD, Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria...

head and neck cancer

Predictors of Readmission in Patients Requiring Free Tissue Reconstruction for Head and Neck Cancer

Certain factors increase the risk of unplanned readmission in the month after head and neck cancer resection requiring free tissue reconstruction, finds an analysis of data from the National Surgical Quality Improvement Program (NSQIP) of the American College of Surgeons.1 Nearly 1 in 10 patients...

head and neck cancer

Good Showing for Trastuzumab/Docetaxel Combination Against Salivary Gland Carcinoma

The combination of trastuzumab (Herceptin) and docetaxel seems to be highly active in patients with unresectable advanced HER2-positive salivary gland carcinoma of the ductal subtype, according to interim data from an open-label, single-arm phase II trial.1 More than two-thirds of patients had a...

head and neck cancer

Benefits Seen From Extending Steroids After Transoral Robotic Surgery for Head and Neck Cancer

Patients undergoing transoral robotic surgery for head and neck cancer may experience improvements in some outcomes when given an extended course of corticosteroids, finds a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Relative to peers given...

head and neck cancer

Nerve Stimulation During Oncologic Neck Dissection May Help to Preserve Shoulder Function

Electrical stimulation of the spinal accessory nerve during neck dissection for head and neck cancer may reduce the development of shoulder dysfunction, according to a double-blind randomized controlled trial.1 A year after surgery, patients given intraoperative electrical stimulation had...

head and neck cancer

Use of Lugol’s Iodine Stain May Reduce the Need for Repeat Resection of Oral and Oropharyngeal Cancers

By identifying residual dysplasia in the tumor bed, Lugol’s iodine staining may improve pathologic outcomes with resection of oral and oropharyngeal cancers, according to interim findings of a UK randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1...

kidney cancer

Is Obesity a Prognostic Factor for Improved Survival in Metastatic Renal Cell Carcinoma?

In a study investigating the clinical and biologic effects of body mass index on treatment outcomes in patients with metastatic renal cell carcinoma, Albiges et al found that obese patients treated with targeted therapy had improved survival and progression-free survival compared with patients with ...

palliative care

Palliative Care 2016: 'Mystery Shopper' Study Finds Barriers to Accessing Palliative Care Services at Major Cancer Centers

A team of researchers, using a novel approach, found that while many cancer centers offer palliative and supportive care services, patients may face challenges when trying to access them. The study showed that expanding awareness and education to patient-facing cancer center employees about such...

palliative care

Palliative Care 2016: Early Palliative Care Improves Coping, Quality of Life for Patients With Incurable Cancers

A randomized clinical trial found that introducing palliative care shortly after a diagnosis of certain metastatic cancers greatly increases a patient’s coping abilities, as well as overall quality of life. Researchers also found that early integration of palliative care results in an...

issues in oncology

Patients With Cancer May Be at Heightened Risk of Injuries During Diagnostic Process

Patients with cancer have heightened risks of unintentional and intentional injuries during the diagnostic process, revealed findings from a large study published by Shen et al in The BMJ. A range of injuries are common, and some are potentially life-threatening, the study showed. The authors...

hematologic malignancies

Autologous Stem Cell Transplant May Age Immune Cells as Much as 30 Years

University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers, by tracking p16INK4a, a molecular marker that has been shown to increase in white blood cells as people age, have uncovered clues suggesting that stem cell transplant is linked to a marked increase in the...

lymphoma

Early Relapse in Follicular Lymphoma: Clinical Trial Data May Guide Management Decisions

Approximately 20% of patients with follicular lymphoma will relapse within 2 years of diagnosis. Although the optimal management of these patients has not been established, clinicians may be guided by data from recent clinical trials, according to Nathan H. Fowler, MD, Associate Professor and...

hematologic malignancies
lymphoma

Higher Baseline Metabolic Tumor Volume May Predict Poorer Outcome in Patients With High Tumor Burden Follicular Lymphoma

In a pooled analysis reported in the Journal of Clinical Oncology, Meignan et al found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG PET-CT) was associated with poorer outcome in patients...

prostate cancer

PSA-Based Computational Model Predicts Time to Relapse After Prostate Cancer Surgery

Approximately one in four patients who undergo radical prostatectomy experience a cancer recurrence. Now a study by Stura et al investigating a prostate-specific antigen (PSA)-based computational model that uses four consecutive postsurgical PSA values has found the mathematical model to be highly...

colorectal cancer

Retinoic Acid May Suppress Colorectal Cancer Development

Retinoic acid may play a critical role in suppressing colorectal cancer in mice and humans, according to researchers at the Stanford University School of Medicine. Mice with the cancer have lower-than-normal levels of the metabolite in their gut, the researchers found. Furthermore, colorectal...

issues in oncology

Outpatient Bloodstream Infections Costly for Pediatric Stem Cell Transplant and Cancer Patients

Pediatric stem cell transplant and cancer patients often are discharged from the hospital with an external central venous line for medications that parents or other caregivers must clean and flush daily to avoid potentially life-threatening infections. If an outpatient develops a bloodstream...

breast cancer

Psychosocial Adjustment, Breast Cancer–Specific Distress in Adolescent Girls From BRCA1/2-Positive and Breast Cancer Families

Adolescent girls from BRCA1/2-positive and breast cancer families appear to have higher self-esteem and similar psychosocial adjustment compared with their peers but experience greater breast cancer–specific distress and perceived risk of breast cancer. Bradbury et al reported these findings...

multiple myeloma

Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

In the phase III CASTOR trial reported in The New England Journal of Medicine, Palumbo et al found that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone markedly improved progression-free survival among patients with relapsed or relapsed and refractory...

solid tumors

Epigenetic Dysregulation of MicroRNA-34A Identified in TP53-Related Cancer Risk

In a genome-wide DNA-methylation analysis to identify genes implicated in Li-Fraumeni syndrome, Samuel et al found a significant association of loss-of-function <em>TP53</em> mutations with differential methylation at the locus encoding microRNA-34A (miR-34A). The study was reported in...

breast cancer

Study Finds Chemotherapy May Be Avoidable in Women With Early Breast Cancer at High Clinical but Low Genomic Risk on 70-Gene Signature Assay

In a phase III trial (MINDACT) reported in The New England Journal of Medicine, Cardoso et al found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical risk but low genomic risk as determined by the 70-gene signature assay (MammaPrint)....

lung cancer

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients With NSCLC and M1a Disease?

Analysis of a large non–small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis. Findings from the study were published by Dai et al in the Journal of Thoracic Oncology. Lung cancer is...

gynecologic cancers

FDA Accepts New Drug Application, Grants Priority Review of Rucaparib for the Treatment of Advanced BRCA-Mutant Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has accepted Clovis Oncology’s New Drug Application (NDA) for accelerated approval of rucaparib and granted Priority Review status to the application with a Prescription Drug User Fee Act date of February 23, 2017. Rucaparib is an...

Cancer Research Institute to Honor Three Scientists for Outstanding Contributions to Cancer Immunotherapy Research

The Cancer Research Institute (CRI), a nonprofit organization established in 1953 to advance biomedical research with the goal of developing lifesaving immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields...

prostate cancer

Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer

In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional radiotherapy in disease-free survival...

skin cancer

Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation

Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...

breast cancer
issues in oncology

Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer

A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...

head and neck cancer

Study Finds More Nodes Should Be Examined to Rule Out Node-Negative Disease in Papillary Thyroid Cancer

The proportion of patients with papillary thyroid cancer identified as having node-negative disease decreased substantially with an increased number of lymph nodes examined, according to an analysis of data from the National Cancer Database. Robinson and colleagues, of Duke University, reported...

skin cancer
lung cancer

Pembrolizumab for Untreated/Progressive Brain Metastases in Melanoma or NSCLC

Sarah B. Goldberg, MD, of Yale University School of Medicine, and colleagues found that pembrolizumab (Keytruda) was active in untreated or progressive brain metastases in melanoma and non–small cell lung cancer (NSCLC), according to a single-center phase II trial reported in The Lancet Oncology....

lung cancer

Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer

Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...

lung cancer

Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy

Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib...

lung cancer

Nivolumab in Recurrent Small Cell Lung Cancer

In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the SCLC...

lung cancer

My Oncologists Make Me Feel Safe Even While Living With Terminal Cancer

Looking back, I’m haunted by what might have been if my advanced non–small cell lung cancer (NSCLC) had been caught in its earliest stage, when perhaps a cure was possible. I certainly presented my physicians with enough clues—shortness of breath, coughing, and some body weakness—to have warranted...

head and neck cancer

FDA Approves Pembrolizumab for Metastatic Head and Neck Squamous Cell Carcinoma

On August 5, 2016, the U. S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or ...

breast cancer

A Complete Guide to Breast Surgery and Reconstruction

BookmarkTitle: Breast Cancer Surgery and Reconstruction: What’s Right for YouAuthor: Patricia Anstett, with photography by Kathleen GalliganPublisher: Rowman & LittlefieldPublication date: June 2, 2016Price: $35.00; hardcover, 224 pages Over the past 2 decades, we have seen tremendous...

Surgical Oncologist Quan P. Ly, MD, FACS, Flees From Vietnam and Finds a Home at the University of Nebraska

After the Vietnam War, close to a million refugees, known as “boat people,” fled Vietnam, hazarding the open ocean on dangerously overloaded vessels. The term “boat people” is often used generically to refer to all the Vietnamese (about 2 million) who left their country by any means between 1975...

issues in oncology
health-care policy

Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years

The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...

leukemia

Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

In a phase III trial reported in The New England Journal of Medicine, Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that treatment with the antibody-drug conjugate inotuzumab ozogamicin resulted in a greater complete remission rate and improved ...

breast cancer

Prevalence of Estrogen Receptor Mutations in Patients With Metastatic Breast Cancer

A new study published online by JAMA Oncology examined the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.1 The activation of the estrogen receptor is a feature of most breast cancers in which estrogen receptor expression is detected. An...

breast cancer

Adding Bevacizumab to Letrozole Improves Progression-Free Survival but Increases Toxicity in Hormone Receptor–Positive Metastatic Breast Cancer

In a phase III trial (CALGB 40503/Alliance) reported in the Journal of Clinical Oncology, Maura N. ­Dickler, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the addition of bevacizumab (Avastin) to first-line endocrine therapy with letrozole improved progression-free...

gynecologic cancers

Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test

Receiving an invitation to undergo screening for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine.1 The study explored the impact of invitation and reminder letters on cervical cancer screening...

breast cancer

Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated

The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer. HRT is used to treat...

lymphoma

Understanding Double-Hit Lymphomas and Optimizing Management

Double-hit lymphomas are a challenging subset of high-grade B-cell lymphomas, previously characterized histologically as diffuse large B-cell lymphoma or B-cell lymphoma unclassifiable with intermediate features between diffuse large B-cell lymphoma and Burkitt lymphoma. Expert guidance in their...

lymphoma

GADOLIN and the Perplexing Role of Obinutuzumab in the Treatment of B-Cell Malignancies

After several dose-finding phase I and II studies in a variety of B-cell malignancies, the potential clinical role of the newer anti-CD20 monoclonal antibody obinutuzumab (Gazyva) remained unclear. These early trials tested low and high doses as well as weekly and every-3-week schedules of...

lymphoma

Phase III Trial Shows Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL

In the phase III GADOLIN trial reported in The Lancet Oncology, Laurie H. Sehn, MD, Chair, British Columbia Cancer Agency Lymphoma Tumor Group, and Clinical Associate Professor at the University of British Columbia, Vancouver, and colleagues, found that adding the anti-CD20 antibody obinutuzumab...

survivorship

Late Cardiac Effects of Cancer Treatment

The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...

lymphoma

Outcomes With Rituximab in DLBCL: Does Gender Matter?

For diffuse large B-cell lymphoma, does the dose of rituximab (Rituxan) matter? Are there patient characteristics that determine outcomes as well as the optimal dose? These questions were explored at the 2016 Pan Pacific Lymphoma Conference by Matthew A. Lunning, DO, Assistant Professor of...

health-care policy
legislation

AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans

“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...

gynecologic cancers

ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer

As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed stage IIIC or IV...

lymphoma

Combination Obinutuzumab Regimen Active in Aggressive Diffuse Large B-Cell Lymphoma

In a small phase Ib/II study, 100% of patients with newly diagnosed diffuse large B-cell lymphoma evaluated thus far responded to treatment with obinutuzumab (Gazyva), lenalidomide (Revlimid), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), investigators from the University of...

Advertisement

Advertisement




Advertisement